MNPR
Income statement / Annual
Last year (2025), Monopar Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Monopar Therapeutics Inc's net income was -$13.72 M.
See Monopar Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$9.90 B
|
$13.01 M
|
$5.60 M
|
$7.59 M
|
$6.49 M
|
$4.07 M
|
$1.97 M
|
$1.77 M
|
$935.32 K
|
$280.36 K
|
| General & Administrative Expenses |
$6.80 B
|
$3.16 M
|
$3.23 M
|
$2.95 M
|
$2.63 M
|
$2.44 M
|
$0.00
|
$1.63 M
|
$1.17 M
|
$912.47 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.80 B
|
$3.16 M
|
$3.23 M
|
$2.95 M
|
$2.63 M
|
$2.44 M
|
$2.36 M
|
$1.63 M
|
$1.17 M
|
$912.47 K
|
| Other Expenses |
-$16.69 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$14.50 M
|
$0.00
|
| Operating Expenses |
$16.70 M
|
$16.16 M
|
$8.83 M
|
$10.54 M
|
$9.13 M
|
$6.51 M
|
$4.32 M
|
$3.40 M
|
$16.60 M
|
$1.19 M
|
| Cost And Expenses |
$16.70 M
|
$16.16 M
|
$8.83 M
|
$10.54 M
|
$9.13 M
|
$6.51 M
|
$4.32 M
|
$3.33 M
|
$16.60 M
|
$1.19 M
|
| Interest Income |
$2.99 M
|
$404.02 K
|
$429.04 K
|
$21.24 K
|
$24.02 K
|
$81.90 K
|
$98.89 K
|
$103.22 K
|
$48.26 K
|
$7.23 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$103.22 K
|
$48.26 K
|
$7.23 K
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.51 M
|
$0.00
|
$3.33 M
|
$2.10 M
|
$1.19 M
|
| EBITDA |
-$13.72 M |
-$15.59 M |
-$8.40 M |
-$10.52 M |
-$9.10 M |
$0.00 |
-$4.22 M |
$0.00 |
-$16.56 M |
$8.03 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.99 M
|
$575.30 K
|
$429.04 K
|
$21.24 K
|
$24.02 K
|
$204.30 K
|
$98.89 K
|
$31.15 K
|
$48.26 K
|
$7.23 K
|
| Income Before Tax |
-$13.72 M
|
-$15.59 M
|
-$8.40 M
|
-$10.52 M
|
-$9.10 M
|
-$6.30 M
|
-$4.22 M
|
-$3.30 M
|
-$16.56 M
|
-$1.18 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$71.62 K
|
$0.00
|
$800.00
|
| Net Income |
-$13.72 M
|
-$15.59 M
|
-$8.40 M
|
-$10.52 M
|
-$9.10 M
|
-$6.30 M
|
-$4.22 M
|
-$3.23 M
|
-$16.56 M
|
-$1.19 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.85 |
-1.36 |
-0.58 |
-0.83 |
-0.73 |
-0.58 |
-0.4 |
-0.31 |
-1.59 |
-0.12 |
| EPS Diluted |
-1.85 |
-1.36 |
-0.58 |
-0.83 |
-0.73 |
-0.58 |
-0.4 |
-0.31 |
-1.59 |
-0.12 |
| Weighted Average Shares Out |
$7.41 M
|
$11.44 M
|
$14.51 M
|
$12.72 M
|
$12.47 M
|
$10.96 M
|
$10.59 M
|
$10.42 M
|
$10.42 M
|
$9.85 M
|
| Weighted Average Shares Out Diluted |
$7.41 M
|
$11.48 M
|
$14.51 M
|
$12.72 M
|
$12.47 M
|
$10.96 M
|
$10.59 M
|
$10.42 M
|
$10.42 M
|
$9.86 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
